Okavax

Description

Okavax vaccine contans attenuated Oka strain of Varicella zoster virus. It is indicated for prevention of Chickenpox in persons from 12 months of age.

Immunization Guideline

A single dose of 0.5 mL is injected subcutaneously to persons not less than 12 months of age and with no history of chickenpox.

Additional information

country-of-manufacture

Thailand

manufacturer

Sanofi Pasteur

package-size

1 Dose

pharmaceutical-form

Lyophilized

preservative

None

route-of-administration

Subcutaneous

vaccine-type

chickenpox

Contraindications

Those suffering from fever, acutely ill, having experienced a previous
anaphylactic reaction to the vaccine or any of its components. Pregnancy.